Effects of pre-transplant L-carnitine supplementation on primary graft dysfunction in liver transplant recipients: a pilot, randomized, placebo-controlled clinical trial

Behrouz Khajeh , Simin Dashti-Khavidaki , Mohsen Nasiri-Toosi, Keyhan Mohammadi, Atefeh Jafari

Abstract


Primary graft dysfunction (PGD) and non-function (PNF) happen in 8.7-24.7% and 0.9-7.2% of liver transplant recipients, respectively. These phenomena increase treatment cost and patients’ death.This study assessed the effect of L-carnitine supplementation on the incidences of PNF/PGD in liver transplant recipients. This randomized, placebo-controlled, clinical trial was performed on  adult liver transplant recipients. Patients took L-carnitine syrup 500 mg three times daily or placebo from the time of including in transplant waiting list until the day of transplant surgery (median 14 days,1-192 days). Thirty-three patients in L-carnitine and 39 patients in placebo group completed the study. Although not statistically significant, PNF and PGD happened less frequently among recipients in L-carnitine compared with placebo group (3% vs. 12.8% for PNF; 15.2% vs. 30.8% for PGD). Alanine aminotransferase (ALT) and aspartate aminotransferase were lower in L-carnitine group at day 3 after transplantation. ALT declined more significantly within 48 h after transplantation in L-carnitine arm (median 120.50 vs. 79 IU/L; P = 0.03). One-month patients’ survival was significantly higher in L-carnitine versus placebo group (97% vs. 74.4%; P = 0.008). The rates of PNF and PGD in L-carnitine group were approximately one-fourth and one-half of placebo group respectively. One-month patients’ survival was higher in L-carnitine group.


Keywords


Ischemia reperfusion injury; L-carnitine; Liver transplantation; Primary graft.

Full Text:

PDF

References


Chen XB, Xu MQ. Primary graft dysfunction after liver transplantation. Hepatobiliary Pancreat Dis Int. 2014;13(2):125-137.

Barrueco-Francionia JE, Seller-Péreza G, Lozano-Saéza R, Arias-Verdúa MD, Quesada-Garcíaa G, Herrera-Gutiérreza ME. Early graft dysfunction after liver transplant: Comparison of different diagnostic criteria in a single-center prospective cohort. Med Intensiva. 2018. pii: S0210-5691(18)30264-X. Doi:10.1016/j.medin.2018.09.004.

Bolondi G, Mocchegiani F, Montali R, Nicolini D, Vivarelli M, De Peitri L. Predictive factors of short term outcome after liver transplantation: A review. World J Gastroenterol. 2016;22(26):5936-5949.

Granger DN, Kvietys PR. Reperfusion injury and reactive oxygen species: The evolution of a concept. Redox Biol. 2015;6:524-551.

Takaya S, Doyle H, Todo S, Irish W, Fung JJ, Starzl TE. Reduction of primary nonfunction with prostaglandin E1 after clinical liver transplantation. Transplant Proc. 1995;27(2):1862-1867.

Bärthel E, Rauchfuss F, Hoyer H, Habrecht O, Jandt K, Götz M, et al. Impact of stable PGI2 analog iloprost on early graft viability after liver transplantation: a pilot study. Clin Transplant. 2012:26(1):E38-E47.

El Gendy HAA, Elsharnouby NM, Koraa A. Perioperative N-acetylcysteine for patients undergoing living donor orthotopic liver transplantation. Ain-Shams J Anaesthesiol. 2015;8(4):483-490.

Hilmi IA, Peng Z, Planinsic RM, Damian D, Dai1 F, Tyurina YY, et al. N-acetylcysteine does not prevent hepatorenal ischaemia-reperfusion injury in patients undergoing orthotopic liver transplantation. Nephrol Dial Transplant. 2010;25(7):2328-2333.

Steiber A, Kerner J, Hoppel CL. Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Aspects Med. 2005;25(5-6):455-473.

Surai PF. Antioxidant action of carnitine: molecular mechanisms and practical applications. EC Vet Sci. 2015;2:66-84.

Abdoli N, Azarmi Y, Eghbal MA. Mitigation of statins-induced cytotoxicity and mitochondrial dysfunction by L-carnitine in freshly-isolated rat hepatocytes. Res Pharm Sci. 2015;10(2):143-151.

Hatamkhani S, Khalili H, Karimzadeh I, Dashti-Khavidaki S, Abdollahi A, Jafari S. Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial. J Gastroenterol Hepatol. 2014; 29(5):997-1004.

Devarbhavi H. An update on drug-induced liver injury. J Clin Exp Hepatol. 2012;2(3):247-259.

Moghaddas A, Dashti-Khavidaki S. Potential protective effects of L-carnitine against neuromuscular ischemia-reperfusion injury: From experimental data to potential clinical applications. Clin Nutr. 2016;35(4):783-790.

Moghaddas A, Dashti-Khavidaki S. L-carnitine and potential protective effects against ischemia-reperfusion injury in noncardiac organs: from experimental data to potential clinical applications. J Diet Suppl. 2018;15(5):740-756.

Jafari A, Khatami MR, Dashti-Khavidaki S, Lessan-Pezeshki M, Abdollahi A, Moghaddas A. Protective effects of L-carnitine against delayed graft function in kidney transplant recipients: A pilot, randomized, double-blinded, placebo-controlled clinical trial.J Ren Nutr. 2017;27(2):113-126.

Puetz U, Tolba RH, Akbar S, Dombrowski F, Minor T. Effects of L-carnitine hydrochloride in the cold ischemic preservation of fatty liver grafts. Transplant Proc. 2001;33(4):2523-2524.

Tolba RH, Pütz U, Decker D, Dombrowski F, Lauschke H. L-carnitine ameliorates abnormal vulnerability of steatotic rat liver to cold ischemic preservation. Transplantation. 2003;76(12): 1681-1686.

Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, et al. Validation of current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943-949.

Organ Procurement and Transplantation Network (OPTN) Policies. 2016. pp: 166-167. Available from: https://optn.transplant.hrsa.gov/media/1200/optn policies.pdf.

Wang ZY, Liu YY, Liu GH, Mao CY. L-carnitine and heart disease. Life Sci. 2018;194:88-97.

Higuchi T. Effects of levocarnitine on cardiac function and renal anemia in hemodialysis patients. Contrib Nephrol. 2018;196:96-100.

Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004;1033:30-41.

Matsuda K, Yuasa H, Watanabe J. Physiologic mechanism-based analysis of dose-dependent gastrointestinal absorption of L-carnitine in rats. Biopharm Drug Dispos. 1998;19(7):465-472.

Kosieradzki M, Rowinski W. Ischemia/reperfusion injury in kidney transplantation; mechanisms and prevention. Transplant Proc. 2008;40(10): 3279-3288


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.